New breast cancer vaccine trial underway at Cleveland Clinic

  • 06 Nov - 12 Nov, 2021
  • Mag The Weekly
  • Mag Files

Researchers at Cleveland Clinic announced that they have started a phase 1 vaccine clinical trial in the fight against one of the deadliest forms of breast cancer: triple negative breast cancer. According to the CDC, triple-negative breast cancer doesn't have any of the receptors that are usually found in the more common types of breast cancer. This form of cancer doesn't respond to hormonal therapy, thus giving patients fewer options for treatment. "We are hopeful that this research will lead to more advanced trials to determine the effectiveness of the vaccine against this highly aggressive type of breast cancer," G. Thomas Budd, M.D., of Cleveland Clinic's Taussig Cancer Institute, said in a press release. Researchers said the intent of the vaccine is to counteract the cancer, though they said it will likely be decades before it is available to the public. For the trial, the vaccine will be administered to around 18-24 people, all given different dosages to test its efficacy. Those chosen for the trial are patients who have been treated for and overcome early-stage triple-negative breast cancer within the past three years, but who are likely to experience recurrence. Researchers said those involved in the study will receive three vaccinations, each two weeks apart, with the purpose of the initial trial to determine the appropriate amount to administer. Researchers anticipate the study will be completed by Sept. 2022.